{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:58:57Z","timestamp":1793505537518,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T00:00:00Z","timestamp":1598400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>IgA nephropathy is the most common glomerulonephritis. Secondary IgA nephropathy complicated with systemic diseases, including psoriasis, is also often reported. Generalized pustular psoriasis is a form of psoriasis characterized by sterile pustules on reddened skin and fever. Infliximab, one of the first-line therapies for severe psoriasis, has also been reported to cause systemic vasculitis and IgA nephropathy. We herein report a case of IgA nephropathy activated during infliximab treatment for generalized pustular psoriasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 28-year-old woman presented with episodic gross hematuria, increasing proteinuria, and renal dysfunction. She had been receiving anti-TNF\u03b1 therapy with infliximab because of generalized pustular psoriasis for 3\u00a0years, but her skin symptoms worsened following withdrawal during pregnancy. After delivery, her skin symptoms improved with the resumption of infliximab, but clinical signs suggested glomerulonephritis, and renal biopsy showed active IgA nephropathy. Infliximab was discontinued, and the combination of corticosteroids, tonsillectomy, and secukinumab, an IL-17A inhibitor, improved both the skin symptoms and the glomerulonephritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In our case, the activity of IgA nephropathy was exacerbated by anti-TNF\u03b1 therapy but was improved by the combination of corticosteroids, tonsillectomy, and an IL-17A inhibitor against the original disease. Autoimmune diseases may underlie the development of secondary IgA nephropathy associated with anti-TNF\u03b1 therapy, and so further studies are needed to better understand the association between molecular-targeted drugs and IgA nephropathy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12882-020-02015-0","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T04:00:32Z","timestamp":1598414432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["IgA nephropathy in a patient receiving infliximab for generalized pustular psoriasis"],"prefix":"10.1186","volume":"21","author":[{"given":"Yuka","family":"Segawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuminao","family":"Kanehisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Seno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuka","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Kusaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-5218","authenticated-orcid":false,"given":"Keiichi","family":"Tamagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"2015_CR1","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1681\/ASN.2005020134","volume":"16","author":"J Barratt","year":"2005","unstructured":"Barratt J, Feehally J. IgA nephropathy. J Am Soc Nephrol. 2005;16:2088\u201397.","journal-title":"J Am Soc Nephrol"},{"key":"2015_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.kint.2018.02.030","volume":"94","author":"MK Saha","year":"2018","unstructured":"Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018;94:674\u201381.","journal-title":"Kidney Int"},{"key":"2015_CR3","doi-asserted-by":"crossref","unstructured":"Benjegerdes, K. E., K. Hyde, D. Kivelevitch and B. Mansouri. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis (Auckl) 2016;6: 131\u2013144.","DOI":"10.2147\/PTT.S98954"},{"key":"2015_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/1346-8138.13306","volume":"43","author":"S Imafuku","year":"2016","unstructured":"Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011\u20137.","journal-title":"J Dermatol"},{"key":"2015_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91:1014\u201321.","journal-title":"Kidney Int"},{"key":"2015_CR6","first-page":"382","volume":"19","author":"J Zadrazil","year":"2006","unstructured":"Zadrazil J, Tichy T, Horak P, et al. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of \u2018psoriatic nephropathy\u2019. J Nephrol. 2006;19:382\u20136.","journal-title":"J Nephrol"},{"key":"2015_CR7","doi-asserted-by":"publisher","first-page":"c221","DOI":"10.1159\/000119716","volume":"108","author":"Y Jiao","year":"2008","unstructured":"Jiao Y, Xu H, Li H, Li X. Mesangial proliferative glomerulonephritis with or without IgA deposits: the morphological characters in psoriasis vulgaris. Nephron Clin Pract. 2008;108:c221\u20135.","journal-title":"Nephron Clin Pract"},{"key":"2015_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1159\/000045450","volume":"82","author":"A Kagan","year":"1999","unstructured":"Kagan A, Husza\u2019r M, Frumkin A, Rapoport J. Reversal of nephrotic syndrome due to AA amyloidosis in psoriatic patients on long-term colchicine treatment. Case report and review of the literature. Nephron. 1999;82:348\u201353.","journal-title":"Nephron"},{"key":"2015_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.4103\/1319-2442.132234","volume":"25","author":"SK Pradhan","year":"2014","unstructured":"Pradhan SK, Beriha SS. Focal segmental glomerulosclerosis associated with psoriasis. Saudi J Kidney Dis Transpl. 2014;25:670\u20131.","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"2015_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00467-007-0487-1","volume":"22","author":"A Bagga","year":"2007","unstructured":"Bagga A, Menon S, Hari P, Mantan M, Dinda A. Nephrotic syndrome preceding psoriasis in children. Pediatr Nephrol. 2007;22:1373\u20136.","journal-title":"Pediatr Nephrol"},{"key":"2015_CR11","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3109\/08860220903180582","volume":"31","author":"H Akoglu","year":"2009","unstructured":"Akoglu H, Dede F, Akoglu G, Gonul II, Odabas AR. Membranoproliferative glomerulonephritis associated with psoriasis vulgaris. Ren Fail. 2009;31:858\u201361.","journal-title":"Ren Fail"},{"key":"2015_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1007\/s10067-006-0422-z","volume":"26","author":"GT Sakellariou","year":"2007","unstructured":"Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol. 2007;26:1132\u20133.","journal-title":"Clin Rheumatol"},{"key":"2015_CR13","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/ijd.12622","volume":"54","author":"N Kluger","year":"2015","unstructured":"Kluger N, Du-Thanh A, Bessis D, Servel MF, Mourad G. Psoriasis-associated IgA nephropathy under infliximab therapy. Int J Dermatol. 2015;54:e79\u201380.","journal-title":"Int J Dermatol"},{"key":"2015_CR14","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1093\/ndt\/gfp314","volume":"24","author":"A Jacquet","year":"2009","unstructured":"Jacquet A, Francois H, Frangie C, et al. IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant. 2009;24:3540\u20132.","journal-title":"Nephrol Dial Transplant"},{"key":"2015_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jaad.2011.01.032","volume":"67","author":"A Robinson","year":"2012","unstructured":"Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279\u201388.","journal-title":"J Am Acad Dermatol"},{"key":"2015_CR16","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3109\/09546634.2013.848258","volume":"25","author":"W Wu","year":"2014","unstructured":"Wu W, Debbaneh M, Moslehi H, Koo J, Liao W. Tonsillectomy as a treatment for psoriasis: a review. J Dermatolog Treat. 2014;25:482\u20136.","journal-title":"J Dermatolog Treat"},{"key":"2015_CR17","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jaad.2014.10.013","volume":"72","author":"TD Rachakonda","year":"2015","unstructured":"Rachakonda TD, Dhillon JS, Florek AG, Armstrong AW. Effect of tonsillectomy on psoriasis: a systematic review. J Am Acad Dermatol. 2015;72:261\u201375.","journal-title":"J Am Acad Dermatol"},{"key":"2015_CR18","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.4049\/jimmunol.1102834","volume":"188","author":"RH Thorleifsdottir","year":"2012","unstructured":"Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol. 2012;188:5160\u20135.","journal-title":"J Immunol"},{"key":"2015_CR19","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.mayocp.2012.04.011","volume":"87","author":"O Sokumbi","year":"2012","unstructured":"Sokumbi O, Wetter DA, Makol A, Warrington KJ. Vasculitis associated with tumor necrosis factor-alpha inhibitors. Mayo Clin Proc. 2012;87:739\u201345.","journal-title":"Mayo Clin Proc"},{"key":"2015_CR20","first-page":"812781","volume":"2013","author":"SS Wei","year":"2013","unstructured":"Wei SS, Sinniah R. Adalimumab (TNF alpha inhibitor) therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient. Case Rep Nephrol. 2013;2013:812781.","journal-title":"Case Rep Nephrol"},{"key":"2015_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s13730-019-00393-5","volume":"8","author":"M Ochi","year":"2019","unstructured":"Ochi M, Toyama T, Ando M, et al. A case of secondary IgA nephropathy accompanied by psoriasis treated with secukinumab. CEN Case Rep. 2019;8:200\u20134.","journal-title":"CEN Case Rep"},{"key":"2015_CR22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.autrev.2014.05.005","volume":"13","author":"M Piga","year":"2014","unstructured":"Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13:873\u20139.","journal-title":"Autoimmun Rev"},{"key":"2015_CR23","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/ndt\/gfh832","volume":"20","author":"MB Stokes","year":"2005","unstructured":"Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400\u20136.","journal-title":"Nephrol Dial Transplant"},{"key":"2015_CR24","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5414\/CNP62234","volume":"62","author":"TW Doulton","year":"2004","unstructured":"Doulton TW, Tucker B, Reardon J, Velasco N. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. Clin Nephrol. 2004;62:234\u20138.","journal-title":"Clin Nephrol"},{"key":"2015_CR25","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jbspin.2006.02.010","volume":"73","author":"B Saint Marcoux","year":"2006","unstructured":"Saint Marcoux, B. And M. De Bandt. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. Joint Bone Spine 2006;73: 710\u2013713.","journal-title":"Joint Bone Spine"},{"key":"2015_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.mehy.2017.07.016","volume":"107","author":"V Di Lernia","year":"2017","unstructured":"Di Lernia V. IgA nephropathy during treatment with TNF-alpha blockers: could it be predicted? Med Hypotheses. 2017;107:12\u20133.","journal-title":"Med Hypotheses"},{"key":"2015_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1586\/1744666X.4.2.275","volume":"4","author":"F Atzeni","year":"2008","unstructured":"Atzeni F, Sarzi-Puttini P. Autoantibody production in patients treated with anti-TNF-alpha. Expert Rev Clin Immunol. 2008;4:275\u201380.","journal-title":"Expert Rev Clin Immunol"},{"key":"2015_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00403-012-1229-1","volume":"304","author":"SB Yilmaz","year":"2012","unstructured":"Yilmaz SB, Cicek N, Coskun M, Yegin O, Alpsoy E. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465\u20139.","journal-title":"Arch Dermatol Res"},{"key":"2015_CR29","doi-asserted-by":"crossref","unstructured":"Furue M, Furue K, Tsuji G, Nakahara T. Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci 2020;21:1275.","DOI":"10.3390\/ijms21041275"},{"key":"2015_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jdermsci.2014.11.008","volume":"77","author":"T Shiga","year":"2015","unstructured":"Shiga T, Sato K, Kataoka S, Sano S. TNF inhibitors directly target Th17 cells via attenuation of autonomous TNF\/TNFR2 signalling in psoriasis. J Dermatol Sci. 2015;77:79\u201381.","journal-title":"J Dermatol Sci"},{"key":"2015_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/exd.13467","volume":"27","author":"JG Krueger","year":"2018","unstructured":"Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018;27:115\u201323.","journal-title":"Exp Dermatol"},{"key":"2015_CR32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","volume":"201","author":"JE Hawkes","year":"2018","unstructured":"Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201:1605\u201313.","journal-title":"J Immunol"},{"key":"2015_CR33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1080\/0886022X.2017.1419972","volume":"40","author":"JR Lin","year":"2018","unstructured":"Lin JR, Wen J, Zhang H, et al. Interleukin-17 promotes the production of underglycosylated IgA1 in DAKIKI cells. Ren Fail. 2018;40:60\u20137.","journal-title":"Ren Fail"},{"key":"2015_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3109\/00365513.2011.652158","volume":"72","author":"FJ Lin","year":"2012","unstructured":"Lin FJ, Jiang GR, Shan JP, et al. Imbalance of regulatory T cells to Th17 cells in IgA nephropathy. Scand J Clin Lab Invest. 2012;72:221\u20139.","journal-title":"Scand J Clin Lab Invest"},{"key":"2015_CR35","doi-asserted-by":"crossref","first-page":"204","DOI":"10.20452\/pamw.2721","volume":"125","author":"E Watorek","year":"2015","unstructured":"Watorek E, Klinger M. IL-17A as a potential biomarker of IgA nephropathy. Pol Arch Med Wewn. 2015;125:204\u20136.","journal-title":"Pol Arch Med Wewn"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-02015-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-02015-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T14:46:31Z","timestamp":1723473991000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-02015-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2015"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-02015-0","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,26]]},"assertion":[{"value":"26 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this Case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"366"}}